Prospective influenza vaccine safety surveillance using fresh data in the Sentinel System

Pharmacoepidemiology and Drug Safety

Volumn 25, Issue 5, 2016, Pages 481-492

  Yih, Weiling Katherine ^a   Kulldorff, Martin ^a   Sandhu, Sukhminder K ^b   Zichittella, Lauren ^a   Maro, Judith C ^a   Cole, David V ^a   Jin, Robert ^a   Kawai, Alison Tse ^a   Baker, Meghan A ^a   Liu, Chunfu ^c   Mcmahill Walraven, Cheryl N ^d   Selvan, Mano S ^e   Platt, Richard ^a   Nguyen, Michael D ^b   Lee, Grace M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c HealthCore   (United States)

^d AETNA   (United States)

^e HUMANA INC   (United States)

Author keywords

Epidemiologic monitoring; Influenza vaccines; Pharmacoepidemiology; Postmarketing product surveillance; Research design; Sequential analysis; Vaccine safety

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; INACTIVATED VACCINE; LIVE VACCINE;

ARTICLE; COHORT ANALYSIS; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; INFLUENZA; INFLUENZA VACCINATION; OUTCOME ASSESSMENT; PHARMACOEPIDEMIOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; PRODUCT SAFETY; RISK FACTOR; SECONDARY ANALYSIS; SEIZURE; SEQUENTIAL ANALYSIS; ADOLESCENT; ADULT; ANAPHYLAXIS; CHILD; COMPARATIVE STUDY; FEMALE; HUMAN; INFANT; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PILOT STUDY; PRESCHOOL CHILD; PROSPECTIVE STUDY; SEIZURES; SENTINEL SURVEILLANCE; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ANAPHYLAXIS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; SEIZURES; SENTINEL SURVEILLANCE; UNITED STATES; VACCINES, ATTENUATED; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84947780816     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3908     Document Type: Article

References (28)

1. Salmon D, Yih WK, Lee G, et al. Success of program linking data sources to monitor H1N1 vaccine safety points to potential for even broader safety surveillance. Health Aff (Millwood) 2012; 31: 2518-2527.
2. McNeil MM, Gee J, Weintraub ES, et al. The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety. Vaccine 2014; 32: 5390-5398.
3. Kulldorff M, Davis RL, Kolczak M, Lewis E, Lieu T, Platt R. A maximized sequential probability ratio test for drug and vaccine safety surveillance. Seq Anal 2011; 30: 58-78.
4. Li L, Kulldorff M. A conditional maximized sequential probability ratio test for pharmacovigilance. Stat Med 2010; 29: 284-295.
5. Greene SK, Kulldorff M, Lewis EM, et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. Am J Epidemiol 2010; 171: 177-188.
6. Lee GM, Greene SK, Weintraub ES, et al. H1N1 and seasonal influenza vaccine safety in the Vaccine Safety Datalink Project. Am J Prev Med 2011; 41: 121-128.
7. Burwen DR, Sandhu SK, MaCurdy TE, et al. Surveillance for Guillain-Barre syndrome after influenza vaccination among the Medicare population, 2009-2010. Am J Public Health 2012; 102: 1921-1927.
8. Yih WK, Lee GM, Lieu TA, et al. Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010. Am J Epidemiol 2012; 175: 1120-1128.
9. Antonova E, Ambrose CS, Kern D, Block SL, Caspard H, Tunceli O. Seasonal influenza vaccination trends from 2007-2011 in privately insured children and adults in the United States. Vaccine 2014; 32: 6563-6568.
10. Nguyen M, Ball R, Midthun K, Lieu TA. The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise. Pharmacoepidemiol Drug Saf 2012; 21(Suppl 1): 291-297.
11. Walsh KE, Cutrona SL, Foy S, et al. Validation of anaphylaxis in the Food and Drug Administration's Mini-Sentinel. Pharmacoepidemiol Drug Saf 2013; 22: 1205-13.
12. Kawai AT, Martin D, Kulldorff M, et al. Febrile seizures following 2010-11 trivalent inactivated influenza vaccine. Pediatrics 2015; 136(4): e848-55. doi: 10.1542/peds.2015-0635 (accessed 14 September 2015).
13. Tse A, Tseng HF, Greene SK, Vellozzi C, Lee GM. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine 2012; 30: 2024-2031.
14. Maro JC, Brown JS, Dal Pan GJ, Kulldorff M. Minimizing signal detection time in postmarket sequential analysis: balancing positive predictive value and sensitivity. Pharmacoepidemiol Drug Saf 2014; 23: 839-848.
15. Kramarz P, DeStefano F, Gargiullo PM, et al. Does influenza vaccination exacerbate asthma? Analysis of a large cohort of children with asthma. Vaccine Safety Datalink Team. Arch Fam Med 2000; 9: 617-623.
16. Klein NP, Hansen J, Lewis E, et al. Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States health maintenance organization. Pediatr Infect Dis J 2010; 29: 613-617.
17. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133: 144-153.
18. Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics 1995; 51: 228-235.
19. Yih WK, Zichittella L, Sandhu SK, et al. Accessing the freshest feasible data for conducting active influenza vaccine safety surveillance. Report to FDA, 8 April 2015. http://mini-sentinel.org/assessments/medical_events/details.aspx?ID=201 (accessed 15 June 2015).
20. Rowhani-Rahbar A, Klein NP, Dekker CL, et al. Biologically plausible and evidence-based risk intervals in immunization safety research. Vaccine 2012; 31: 271-277.
21. Greene SK, Kulldorff M, Yin R, et al. Near real-time vaccine safety surveillance with partially accrued data. Pharmacoepidemiol Drug Saf 2011; 20: 583-590.
22. Leroy Z, Broder K, Menschik D, Shimabukuro T, Martin D. Febrile seizures after 2010-2011 influenza vaccine in young children, United States: a vaccine safety signal from the Vaccine Adverse Event Reporting System. Vaccine 2012; 30: 2020-2023.
23. Kawai AT, Li L, Kulldorff M, et al. Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barre syndrome, encephalitis, or anaphylaxis in the 2012-2013 season. Pharmacoepidemiol Drug Saf 2014; 23: 548-553.
24. Cano M. End-of-season update: 2013-2014 influenza vaccine safety monitoring. Presentation to Advisory Committee on Immunization Practices, 25 June 2014. http://webcache.googleusercontent.com/search?q=cache:DmPUkzGRZKEJ:www.cdc.gov/vaccines/acip/meetings/downloads/slides-2014-06/Influenza-03-Cano.pdf+&cd=1&hl=en&ct=clnk&gl=us (accessed 9 June 2015).
25. Dodd CN, Romio SA, Black S, et al. International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. Vaccine 2013; 31: 4448-4458.
26. Cocoros NM, Jankosky C, Kawai AT, et al. Influenza vaccines and febrile seizures in the 2013-2014 and 2014-2015 influenza seasons. Mini-Sentinel CBER/PRISM surveillance protocol, 11 September 2015. http://mini-sentinel.org/assessments/medical_events/details.aspx?ID=294 (accessed 28 September 2015).
27. Advisory Committee on Immunization Practices (ACIP); ACIP Influenza Work Group; Immunization Safety Office, National Center for Emerging and Zoonotic Infectious Diseases; Influenza Div, Immunization Services Div, National Center for Immunization and Respiratory Diseases; CDC. Update: Recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine (Afluria) in the United States during 2010-11. MMWR Morb Mortal Wkly Rep 2010;59:989-992. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5931a4.htm (accessed 9 June 2015).
28. Food and Drug Administration. Afluria (CSL Ltd.) influenza virus vaccine: label change-risk of fever and febrile seizure. Posted 30 July 2010. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm220764.htm (accessed 9 June 2015).